文献速递生殖医学

在自然周期冻融胚胎移植中加入短疗程促性腺激素释放激素拮抗剂和促性腺激素可安排移植日而不影响活产

Adding short-duration gonadotropin-releasing hormone antagonist and gonadotropin to natural cycle frozen embryo transfer allowed scheduling of transfer day without compromising live birth.
PubMed 文献 · Fertil Steril · 2025-01-30

本研究为美国单一生育诊所网络的回顾性队列,纳入2019年1月至2022年4月所有排卵患者的自然周期冻融胚胎移植(FET),比较短疗程促性腺激素释放激素拮抗剂(1安瓿/天)联合低剂量促性腺激素(75 IU/天)延迟排卵以灵活安排移植日的方案(计划组,114/1087,10.5%)与未延迟的自然周期FET。计划组人绒毛膜促性腺激素阳性率和临床妊娠率显著升高,活产率较高但未达统计学显著(57.0% vs 49.4%;RR 1.15,95%CI 0.97-1.36)。作者认为该方案不降低活产,可作为提供安排灵活性的替代方案。

要点

  • 计划组hCG阳性率81.6% vs 64.3%(RR 1.26,95%CI 1.15-1.38),临床妊娠率68.4% vs 57.1%(RR 1.21,95%CI 1.06-1.38)。
  • 计划组活产率57.0% vs 49.4%(RR 1.15,95%CI 0.97-1.36),未达统计学显著。
  • 作者认为该方案不降低活产,可作为灵活安排移植日的替代FET方案。

核心结论

  • 使用短疗程促性腺激素释放激素拮抗剂联合低剂量促性腺激素的计划自然周期FET方案,与D13传统自然周期FET相比未降低活产。
  • 作者认为该方案可作为替代FET方案,在保持自然周期方案的同时为安排FET日提供灵活性,并可能使更多诊所提供自然周期FET。

研究设计与样本

  • 美国单一生育诊所网络的回顾性队列,纳入2019年1月至2022年4月所有排卵患者的自然周期FET。
  • 共1087个自然周期FET符合纳入标准,其中114个(10.5%)使用计划自然周期FET方案。
  • 平均年龄35岁(四分位距33-38岁)。

主要发现

  • 计划组与自然周期组在扳机日的雌二醇水平分别为318 vs 249 pg/mL,促黄体生成素水平分别为5.7 vs 13.4 mIU/mL,峰值子宫内膜厚度分别为9.4 vs 9.7 mm。
  • 计划组hCG阳性率81.6% vs 自然周期组64.3%(RR 1.26,95%CI 1.15-1.38),临床妊娠率68.4% vs 57.1%(RR 1.21,95%CI 1.06-1.38)。
  • 计划组活产率57.0% vs 自然周期组49.4%(RR 1.15,95%CI 0.97-1.36),未达统计学显著。
  • 胚胎植入前非整倍体遗传学检测在计划组占76.3%(n=87),在自然周期组占68.9%(n=670);对胚胎植入前非整倍体遗传学检测周期的亚组分析结果相似。

临床怎么用

  • 作者认为该方案可作为替代FET方案,在保持自然周期方案的同时为安排FET日提供灵活性,并可能使更多诊所提供自然周期FET。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether there is an association between the type of natural cycle frozen embryo transfer (FET) (scheduled vs. traditional) and live birth outcomes. DESIGN: Retrospective cohort of all natural cycle FETs across a single network of fertility clinics in the United States. SUBJECTS: All natural cycle FETs performed in ovulatory patients between January 2019 and April 2022. EXPOSURE: Scheduled natural cycle FET cycles that received a short-duration of gonadotropin-releasing hormone antagonist (1 ampule/d) with low-dose gonadotropins (75 IU/d) to delay ovulation to enable more flexible scheduling of the FET were compared with cycles without delay. MAIN OUTCOME MEASURES: Live birth. RESULTS: There were a total of 1,087 natural cycle FETs that met the inclusion criteria. The scheduled natural cycle FET protocol was used in 114 (10.5%) of these cycles. The mean age was 35 (interquartile range, 33-38) years. Preimplantation genetic testing for aneuploidy was used in 76.3% (n = 87) of scheduled natural cycle FET cycles and 68.9% (n = 670) of natural cycle FET cycles. The scheduled natural cycle FET group had a significantly higher estradiol level (318 vs. 249 pg/mL) and a lower luteinizing hormone level (5.7 vs. 13.4 mIU/mL) at ovulatory trigger but a comparable peak endometrial thickness (9.4 vs. 9.7 mm) compared with the natural cycle FET group. Overall, there was a significant increase in the rates of positive human chorionic gonadotropin (scheduled natural cycle, 81.6%, vs. natural cycle, 64.3%; relative risk [RR], 1.26 [95% confidence interval {CI}, 1.15-1.38]) and clinical pregnancy (scheduled natural cycle, 68.4%, vs. natural cycle, 57.1%; RR, 1.21 [95% CI, 1.06-1.38]) in the scheduled natural cycle group. There were a higher proportion of live births in the scheduled natural cycle group; however, this did not reach statistical significance (scheduled natural cycle, 57.0%, vs. natural cycle, 49.4%; RR, 1.15 [95% CI, 0.97-1.36]). A subanalysis of preimplantation genetic testing for aneuploidy cycles yielded similar results. CONCLUSION: A scheduled natural cycle FET protocol using a short duration of gonadotropin-releasing hormone antagonist along with low-dose gonadotropin add-back did not reduce live birth compared with traditional natural cycle FET cycles. These results suggest that this is an alternative FET protocol that may serve as a viable strategy to provide flexibility in scheduling the day of FET while still allowing a patient to undergo a natural cycle protocol. This protocol modification may enable more clinics to offer natural cycle FET.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Borazjani A, Flannagan KSJ, O'Brien JE, et al. Adding short-duration gonadotropin-releasing hormone antagonist and gonadotropin to natural cycle frozen embryo transfer allowed scheduling of transfer day without compromising live birth. Fertil Steril. 2025. PMID: 39889922. doi:10.1016/j.fertnstert.2025.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。